HIV-1 viral infectivity factor interacts with TP53 to induce G2 cell cycle arrest and positively regulate viral replication

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 48, 2010, Pages 20798-20803

  Izumi, Taisuke ^a,b   Io, Katsuhiro ^a   Matsui, Masashi ^a   Shirakawa, Kotaro ^a,b   Shinohara, Masanobu ^a   Nagai, Yuya ^a   Kawahara, Masahiro ^a   Kobayashi, Masayuki ^a   Kondoh, Hiroshi ^a   Misawa, Naoko ^a   Koyanagi, Yoshio ^a   Uchiyama, Takashi ^c   Takaori Kondo, Akifumi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b The Japan Foundation   (Japan)

^c Kitano Hospital   (Japan)

Author keywords

AIDS; APOBEC3G; HXB2; Infectivity; NL4 3

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTIVITY FACTOR PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL STRAIN HCT116; CELL STRAIN HEK293; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ANTAGONISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTAGENESIS; NONHUMAN; NUCLEAR EXPORT SIGNAL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; UBIQUITINATION; VIRUS INFECTIVITY; VIRUS MUTANT; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 78650552132     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1008076107     Document Type: Article

References (48)

1. Stopak K, de Noronha C, Yonemoto W, Greene WC (2003) HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12:591-601.
2. Sheehy AM, Gaddis NC, Malim MH (2003) The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9:1404-1407.
3. Yu X, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV- 1 Vif-Cul5-SCF complex. Science 302:1056-1060.
4. Kobayashi M, Takaori-Kondo A, Miyauchi Y, Iwai K, Uchiyama T (2005) Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function. J Biol Chem280:18573-18578.
5. Sakai K, Dimas J, Lenardo MJ (2006) The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proc Natl Acad Sci USA 103:3369-3374.
6. Wang J, et al. (2007) The Vif accessory protein alters the cell cycle of human immunodeficiency virus type 1 infected cells. Virology 359:243-252.
7. Taylor WR, Stark GR (2001) Regulation of the G2/M transition by p53. Oncogene 20: 1803-1815.
8. Giono LE, Manfredi JJ (2006) The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 209:13-20.
9. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408:307-310.
10. Bunz F, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497-1501.
11. Wang XW, et al. (1999) GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci USA 96:3706-3711.
12. Hermeking H, et al. (1997) 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1:3-11.
13. He J, et al. (1995)Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69:6705-6711.
14. Re F, Braaten D, Franke EK, LubanJ (1995) Human immunodeficiency virus type 1Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B. J Virol 69:6859-6864.
15. Nakai-Murakami C, et al. (2007) HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination. Oncogene 26:477-486.
16. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V (2003) Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem 278:25879-25886.
17. Izumi T, et al. (2009) MDM2 is a novel E3 ligase for HIV-1 Vif. Retrovirology 6:1.
18. Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
19. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299-303.
20. Tao W, Levine AJ (1999) Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 96:3077-3080.
21. Flatt PM, Tang LJ, Scatena CD, Szak ST, Pietenpol JA (2000) p53 regulation of G(2) checkpoint is retinoblastoma protein dependent. Mol Cell Biol 20:4210-4223.
22. Cheng J, Haas M (1990) Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol 10:5502-5509.
23. Argentini M, Barboule N, Wasylyk B (2001) The contribution of the acidic domain of MDM2 to p53 and MDM2 stability. Oncogene 20:1267-1275.
24. Iwakuma T, Lozano G (2003) MDM2, an introduction. Mol Cancer Res 1:993-1000.
25. Kawai H, Wiederschain D, Yuan ZM (2003) Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol Cell Biol 23:4939-4947.
26. Meulmeester E, et al. (2003) Critical role for a central part of Mdm2 in the ubiquitylation of p53. Mol Cell Biol 23:4929-4938.
27. Ganguli G, Wasylyk B (2003) p53-independent functions of MDM2. Mol Cancer Res 1: 1027-1035.
28. Grossman SR, et al. (1998) p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell 2:405-415.
29. Kawai H, Nie L, Wiederschain D, Yuan ZM (2001) Dual role of p300 in the regulation of p53 stability. J Biol Chem 276:45928-45932.
30. Honda R, Yasuda H (1999) Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J 18:22-27.
31. Kamijo T, et al. (1998) Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci USA 95:8292-8297.
32. Tao W, Levine AJ (1999) P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA 96:6937-6941.
33. Hsieh JK, et al. (1999) RB regulates the stability and the apoptotic function of p53 via MDM2. Mol Cell 3:181-193.
34. Xiao ZX, et al. (1995) Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature 375:694-698.
35. Yap DB, Hsieh JK, Chan FS, Lu X (1999) mdm2: A bridge over the two tumour suppressors, p53 and Rb. Oncogene 18:7681-7689.
36. Moll UM, Petrenko O (2003) The MDM2-p53 interaction. Mol Cancer Res 1:1001-1008.
37. Akari H, et al. (2004) High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site. J Biol Chem 279:12355-12362.
38. Schröfelbauer B, Hakata Y, Landau NR (2007) HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. Proc Natl Acad Sci USA 104:4130-4135.
39. Wen X, Duus KM, Friedrich TD, de Noronha CM (2007) The HIV1 protein Vpr acts to promote G2 cell cycle arrest by engaging a DDB1 and Cullin4A-containing ubiquitin ligase complex using VprBP/DCAF1 as an adaptor. J Biol Chem 282:27046-27057.
40. Hobbs WE,, II, DeLuca NA (1999) Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. J Virol 73:8245-8255.
41. Øster B, Bundgaard B, Höllsberg P (2005) Human herpesvirus 6B induces cell cycle arrest concomitant with p53 phosphorylation and accumulation in T cells. J Virol 79:1961-1965.
42. Castillo JP, et al. (2005) Human cytomegalovirus IE1-72 activates ataxia telangiectasia mutated kinase and a p53/p21-mediated growth arrest response. J Virol 79:11467-11475.
43. Song YJ, Stinski MF (2005) Inhibition of cell division by the human cytomegalovirus IE86 protein: Roleof thep53pathway or cyclin-dependent kinase 1/cyclin B1. J Virol 79:2597-2603.
44. Chen Z, Knutson E, Wang S, Martinez LA, Albrecht T (2007) Stabilization of p53 in human cytomegalovirus-initiated cells is associated with sequestration of HDM2 and decreased p53 ubiquitination. J Biol Chem 282:29284-29295.
45. Goh WC, et al. (1998) HIV-1 Vpr increases viral expression by manipulation of the cell cycle: A mechanism for selection of Vpr in vivo. Nat Med 4:65-71.
46. Vallanti G, Lupo R, Federico M, Mavilio F, Bovolenta C (2005) T lymphocytes transduced with a lentiviral vector expressing F12-Vif are protected from HIV-1 infection in an APOBEC3G-independent manner. Mol Ther 12:697-706.
47. Porcellini S, et al. (2009) The F12-Vif derivative Chim3 inhibits HIV-1 replication in CD4+ T lymphocytes and CD34+-derived macrophages by blocking HIV-1 DNA integration. Blood 113:3443-3452.
48. Porcellini S, et al. (2010) Chim3 confers survival advantage to CD4+ T cells upon HIV-1 infection by preventing HIV-1 DNA integration and HIV-1-induced G2 cell-cycle delay. Blood 115:4021-4029.